Key result
High-dose IVGG reduces Kawasaki disease coronary artery lesions from ~20% to under 5%.
Why the study?
Five major problems in Kawasaki disease must still be solved, warranting a review of its history, clinical features, diagnosis, laboratory findings, cardiovascular complications, treatment, epidemiology, and pathology.
Answers are grounded in this paper and cite their sources.
This comprehensive review by Dr. Tomisaku Kawasaki summarizes the clinical diagnosis, cardiovascular complications, epidemiological trends, and dose-dependent efficacy of IVGG therapy in Kawasaki disease, while highlighting five major unresolved clinical and etiological challenges.
This paper discusses the brief history of Kawasaki disease, its main clinical features, diagnosis, main laboratory findings, cardiovascular complications in brief, treatment, epidemiology mainly in Japan, a summary of the pathology and concludes with five major problems which must be solved.
No takes yet. Share an insight, caveat, or question.
Tomisaku Kawasaki (1995) conducted a review in Kawasaki disease (acute febrile mucocutaneous lymph node syndrome). Intravenous gammaglobulin (IVGG) plus aspirin vs. Aspirin alone or lower-dose IVGG regimens was evaluated on Coronary artery aneurysm formation.
Synapse has enriched 10 related papers. Consider them for comparative context: